v3.26.1
Consolidated Statements of Stockholders' Deficit - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance, beginning at Sep. 30, 2024 $ 239,057 $ 469,969,333 $ (543,284,900) $ (73,076,510)
Balance, beginning (in shares) at Sep. 30, 2024 23,905,635      
Increase (Decrease) in Stockholders' Equity        
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 10,000 1,726,042   1,736,042
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 1,000,000      
Stock-based compensation expense   3,672,420   3,672,420
Net Income (Loss)     17,377,614 17,377,614
Balance, ending at Dec. 31, 2024 $ 249,057 475,367,795 (525,907,286) (50,290,434)
Balance, ending (in shares) at Dec. 31, 2024 24,905,635      
Balance, beginning at Sep. 30, 2024 $ 239,057 469,969,333 (543,284,900) (73,076,510)
Balance, beginning (in shares) at Sep. 30, 2024 23,905,635      
Increase (Decrease) in Stockholders' Equity        
Net Income (Loss)       (49,132,094)
Balance, ending at Jun. 30, 2025 $ 434,791 554,792,478 (592,416,994) (37,189,725)
Balance, ending (in shares) at Jun. 30, 2025 43,479,051      
Balance, beginning at Dec. 31, 2024 $ 249,057 475,367,795 (525,907,286) (50,290,434)
Balance, beginning (in shares) at Dec. 31, 2024 24,905,635      
Increase (Decrease) in Stockholders' Equity        
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 9,268 1,401,947   1,411,215
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 926,742      
Issuance of common stock and common stock warrants in connection with exercise of common stock warrants $ 70,746 60,980,296   61,051,042
Issuance of common stock and common stock warrants in connection with exercise of common stock warrants (in shares) 7,074,637      
Stock-based compensation expense   1,722,778   1,722,778
Net Income (Loss)     (46,357,206) (46,357,206)
Balance, ending at Mar. 31, 2025 $ 329,071 539,472,816 (572,264,492) (32,462,605)
Balance, ending (in shares) at Mar. 31, 2025 32,907,014      
Increase (Decrease) in Stockholders' Equity        
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 105,609 13,612,639   13,718,248
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 10,560,976      
Issuance of common stock in connection with conversion of convertible promissory note $ 111 24,889   25,000
Issuance of common stock in connection with conversion of convertible promissory note (in shares) 11,061      
Stock-based compensation expense   1,682,134   1,682,134
Net Income (Loss)     (20,152,502) (20,152,502)
Balance, ending at Jun. 30, 2025 $ 434,791 554,792,478 (592,416,994) (37,189,725)
Balance, ending (in shares) at Jun. 30, 2025 43,479,051      
Balance, beginning at Sep. 30, 2025 $ 538,873 572,983,229 (605,709,763) $ (32,187,661)
Balance, beginning (in shares) at Sep. 30, 2025 53,887,233     53,887,233
Increase (Decrease) in Stockholders' Equity        
Issuance of common stock in connection with exercise of warrants $ 4,286 903,055   $ 907,341
Issuance of common stock in connection with exercise of warrants (in shares) 428,571      
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 102,271 14,774,833   14,877,104
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 10,227,166      
Issuance of common stock in connection with conversion of convertible promissory note $ 136 30,600   30,736
Issuance of common stock in connection with conversion of convertible promissory note (in shares) 13,600      
Stock-based compensation expense   881,150   881,150
Net Income (Loss)     (23,058,135) (23,058,135)
Balance, ending at Dec. 31, 2025 $ 645,566 589,572,867 (628,767,898) (38,549,465)
Balance, ending (in shares) at Dec. 31, 2025 64,556,570      
Balance, beginning at Sep. 30, 2025 $ 538,873 572,983,229 (605,709,763) $ (32,187,661)
Balance, beginning (in shares) at Sep. 30, 2025 53,887,233     53,887,233
Increase (Decrease) in Stockholders' Equity        
Net Income (Loss)       $ (47,830,487)
Balance, ending at Jun. 30, 2026 $ 1,870,971 641,276,712 (653,540,250) $ (10,392,567)
Balance, ending (in shares) at Jun. 30, 2026 187,096,998     187,096,998
Balance, beginning at Dec. 31, 2025 $ 645,566 589,572,867 (628,767,898) $ (38,549,465)
Balance, beginning (in shares) at Dec. 31, 2025 64,556,570      
Increase (Decrease) in Stockholders' Equity        
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 250,000 6,090,292   6,340,292
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 25,000,000      
Issuance of common stock in connection with conversion of convertible promissory note $ 150,577 6,759,423   6,910,000
Issuance of common stock in connection with conversion of convertible promissory note (in shares) 15,057,649      
Stock-based compensation expense   757,483   757,483
Net Income (Loss)     (4,453,081) (4,453,081)
Balance, ending at Mar. 31, 2026 $ 1,046,143 603,180,065 (633,220,979) (28,994,771)
Balance, ending (in shares) at Mar. 31, 2026 104,614,219      
Increase (Decrease) in Stockholders' Equity        
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs $ 581,496 26,374,261   26,955,756
Sale of common stock and warrants and issuance of common stock in connection with exercise of warrants, net of issuance costs (in shares) 58,149,573      
Issuance of common stock in connection with conversion of convertible promissory note $ 243,332 10,930,716   11,174,048
Issuance of common stock in connection with conversion of convertible promissory note (in shares) 24,333,206      
Stock-based compensation expense   791,671   791,671
Net Income (Loss)     (20,319,272) (20,319,272)
Balance, ending at Jun. 30, 2026 $ 1,870,971 $ 641,276,712 $ (653,540,250) $ (10,392,567)
Balance, ending (in shares) at Jun. 30, 2026 187,096,998     187,096,998